Arvinas ARVN 深 滬
已收盤 08-01 16:00:00 美东时间
7.42
-0.020
-0.27%
華盛通- 最 高7.45
- 今 開7.33
- 成交量 146.58万股
- 最 低 7.22
- 昨 收 7.44
- 總市值 5.42亿
- 52周最高 29.6106
- 市盈率 靜 --
- 換手率 2.01%
- 52周最低 5.90
- 委 比 -98.57%
- 總股本 7299.14万
- 歷史最高 108.465
- 量 比 0.75
- 振 幅 3.09%
- 歷史最低 5.90
- 每 手 1
- 風險率 8.98%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company focused on targeted protein degradation, announced that its management will discuss the second-quarter 2025 financial results and provide a corporate update during a live webcast on August 6, 2025, at 8:00 a.m. ET. The webcast can be accessed via the company’s investor page, with a replay available post-event.
07-30 20:05
Celcuity Stock Skyrockets On Breakthrough Trial Data For Heavily Pretreated Breast Cancer
Celcuity shares jump as gedatolisib shows strong efficacy in HR+/HER2- breast cancer Phase 3 trial, with FDA filing expected in late 2025.
07-28 21:42
Arvinas CEO John Houston to retire
Arvinas (NASDAQ:ARVN) announced that president and CEO John Houston plans to retire from his roles at the biotech company following the appointment of a successor. The company has initiated a search f...
07-09 19:36
Arvinas Begins CEO Search as Longtime Leader John Houston Plans Exit From Top Role, Will Stay On as Board Chair
Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., Chairperson, Chief
07-09 19:05
Arvinas Announces Retirement of Chief Executive Officer and Succession Plan
John Houston, Ph.D., CEO and President of Arvinas, has announced his plans to retire upon the appointment of a new CEO. Houston will remain as Chairperson of Arvinas’ Board of Directors and the Board has initiated a search for his successor. Houston joined Arvinas in 2017 and has significantly advanced targeted protein degradation, successfully leading the company through pivotal milestones. The Board expresses gratitude for his leadership and is...
07-09 11:00
Arvinas Presents Data From Preclinical Studies Of ARV-393, PROTAC B-Cell Lymphoma 6 Protein Degrader, At EHA 2025 Congress
– ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (also known as AITL) and transformed follicular lymphoma –– In combination with small
06-13 19:04
针对乳腺癌 Arvinas和辉瑞(PFE.US)联合开发的明星PROTAC新药申报上市
今日，Arvinas和辉瑞公司(PFE.US)宣布已为其联合开发的明星PROTAC分子vepdegestrant向美国FDA提交新药申请(NDA)。
06-09 21:21
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
Arvinas and Pfizer submitted an NDA to the FDA for vepdegestrant, a PROTAC ER degrader, to treat ESR1-mutated ER+/HER2- advanced or metastatic breast cancer. The application is supported by the Phase 3 VERITAC-2 trial, which demonstrated superior progression-free survival compared to fulvestrant. Results were presented at the 2025 ASCO Annual Meeting and published in the New England Journal of Medicine. Vepdegestrant has been granted Fast Track d...
06-06 11:00
Arvinas To Present New Preclinical Data For ARV-393 At European Hematology Association Meeting
– Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (AITL) and transformed
06-05 20:31
